1. Home
  2. BTT vs FTRE Comparison

BTT vs FTRE Comparison

Compare BTT & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Municipal 2030 Target Term Trust

BTT

BlackRock Municipal 2030 Target Term Trust

HOLD

Current Price

$22.79

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$16.75

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTT
FTRE
Founded
2012
1996
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BTT
FTRE
Price
$22.79
$16.75
Analyst Decision
Hold
Analyst Count
0
8
Target Price
N/A
$12.64
AVG Volume (30 Days)
151.1K
1.4M
Earning Date
01-01-0001
11-05-2025
Dividend Yield
2.95%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,759,900,000.00
Revenue This Year
N/A
$3.17
Revenue Next Year
N/A
$0.11
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.88
52 Week Low
$18.90
$3.97
52 Week High
$21.86
$20.26

Technical Indicators

Market Signals
Indicator
BTT
FTRE
Relative Strength Index (RSI) 63.50 63.79
Support Level $22.24 $17.06
Resistance Level $22.54 $17.69
Average True Range (ATR) 0.17 0.81
MACD 0.04 -0.14
Stochastic Oscillator 83.87 49.13

Price Performance

Historical Comparison
BTT
FTRE

About BTT BlackRock Municipal 2030 Target Term Trust

Blackrock Municipal 2030 Target Term Trust is a United States-based closed-end management investment company. The investment objective of the company is to provide current income exempt from regular federal income tax and to return $25.00 per common share to holders of common shares. The trust seeks to achieve its investment objectives by investing a majority of its assets in municipal bonds exempt from U.S. federal income taxes.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Share on Social Networks: